losartan has been researched along with Muscular Dystrophy in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan treatment was associated with significant impressive improvement in muscle strength and amelioration of fibrosis." | 5.38 | Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. ( Aga-Mizrachi, S; Barak, V; Brunschwig, Z; Elbaz, M; Ettinger, K; Kassis, I; Nevo, Y; Yanay, N, 2012) |
| " Inhibition of TGFβ signaling by Losartan treatment greatly improved the phenotype of myopathies associated with laminin-α2-deficient congenital muscular dystrophy." | 4.88 | TGFβ signaling: its role in fibrosis formation and myopathies. ( Cohn, RD; MacDonald, EM, 2012) |
| "To elucidate the reliability of MRI as a non-invasive tool for assessing in vivo muscle health and pathological amelioration in response to Losartan (Angiotensin II Type 1 receptor blocker) in DyW mice (mouse model for Laminin-deficient Congenital Muscular Dystrophy Type 1A)." | 3.81 | Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). ( Accorsi, A; Girgenrath, M; Kumar, A; Vohra, R; Walter, G, 2015) |
| "Losartan treatment was associated with significantly increased serum tumor necrosis factor alpha (TNF-α) level, p65 nuclei accumulation, and decreased muscle IκB-β protein level, indicating NFκB activation." | 1.42 | Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A. ( Elbaz, M; Laban, S; Mitrani-Rosenbaum, S; Nevo, Y; Rabie, M; Yanay, N, 2015) |
| "Losartan treatment was associated with significant impressive improvement in muscle strength and amelioration of fibrosis." | 1.38 | Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. ( Aga-Mizrachi, S; Barak, V; Brunschwig, Z; Elbaz, M; Ettinger, K; Kassis, I; Nevo, Y; Yanay, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elbaz, M | 2 |
| Yanay, N | 2 |
| Laban, S | 1 |
| Rabie, M | 1 |
| Mitrani-Rosenbaum, S | 1 |
| Nevo, Y | 2 |
| Vohra, R | 1 |
| Accorsi, A | 1 |
| Kumar, A | 1 |
| Walter, G | 1 |
| Girgenrath, M | 1 |
| Aga-Mizrachi, S | 1 |
| Brunschwig, Z | 1 |
| Kassis, I | 1 |
| Ettinger, K | 1 |
| Barak, V | 1 |
| MacDonald, EM | 1 |
| Cohn, RD | 1 |
1 review available for losartan and Muscular Dystrophy
| Article | Year |
|---|---|
TGFβ signaling: its role in fibrosis formation and myopathies.
Topics: Animals; Caveolin 3; Disease Models, Animal; Fibrosis; Humans; Losartan; MicroRNAs; Muscle, Skeletal | 2012 |
3 other studies available for losartan and Muscular Dystrophy
| Article | Year |
|---|---|
Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A.
Topics: Animals; Apoptosis; Caspase 3; Disease Models, Animal; Ferritins; Humans; Inhibitor of Apoptosis Pro | 2015 |
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Laminin; Losarta | 2015 |
Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Disease Models, Animal; Fluores | 2012 |